Advinus Therapeutics Company Profile
Advinus Therapeutics is a research-based Pharmaceutical Company founded by leading global pharmaceutical executives and promoted by the TATA Group. The company is the first of its kind in India to offer end-to-end development services to the global Pharma, Agro and Biotech industries and at the same time creating long-term value through internal and collaborative innovative Drug Discovery. Advinus Drug Discovery, located in a state of the art facility in Pune (near Mumbai), is developing its own drug candidates with the objective of out-licensing them at preclinical or clinical stages. The therapeutic areas of focus of these programs are in Metabolic Diseases, Inflammatory Diseases and neglected diseases such as Leishmaniasis. Advinusâ Pharmaceutical development operation is based out of Bangalore and is set on a 9-acre campus with 240,000 sq. ft of modern facilities. This center progresses our discovery compounds from Pune through pre-clinical development by performing all IND track studies and also by managing the early clinical development of these compounds. The Bangalore center additionally offers its capabilities of end-to-end pre-clinical to early clinical development as services for pharmaceutical product development. The services areas include Process Development, Drug Metabolism and Pharmacokinetics, Clinical Pharmacology, Safety Assessment and Analytical R&D. The Bangalore center is also one of the most accredited R&D centers of India with certification from AAALAC International and from the German, Dutch and Indian authorities for GLP compliance. In its management and senior leadership the team, the Company has over 150 years of drug discovery and drug development experience in U.S. large Pharmaceutical companies, with specific experience of handling dozens of IND and NDA filings.
News Articles
TAKEDA AND ADVINUS INITIATE MULTI-YEAR DRUG DISCOVERY COLLABORATION
Osaka, Japan, and Bangalore, India, October 3, 2012 – Takeda Pharmaceutical Company Limited (Takeda) and Advinus Therapeutics Ltd. (Advinus) jointly announced today that they have entered into an ag...
To Boost Productivity, India’s Advinus, Takeda Team Up For R&D Across Therapies
Takeda looks to ride on Advinus’ broad early-stage pipeline while also generating new INDs.
Takeda, Advinus in drug discovery deal
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Advinus Therapeutics Ltd. (Bangalore, India) partnered to discover compounds against predefined targets for inflammation, CNS and metabolic diseases. Un...
Takeda and Advinus enter a multi year drug discovery pact
Takeda Pharmaceutical Company Limited and Advinus Therapeutics jointly announced that they have entered into an agreement to initiate a three-year discovery collaboration focused on novel targets for...
Takeda, Advinus initiated multi-year drugs discovery collaboration
Takeda Pharmaceutical, a Japanese research-based pharmaceutical company, and Advinus Therapeutics, a privately held research-based pharmaceutical company based in India, have entered into an agreement...
[Advinus] to discover new therapeutics for [Takeda] during three-year collaboration
Indian drug discovery firm [Advinus Therapeutics Ltd.] has found another partner in Big Pharma, this time agreeing to find new CNS, inflammation, and metabolic disease therapeutics for [Takeda Pharmac...
Drugs and Medications
None
PubMed Articles
Synthesis of novel sugar-lactam conjugates using the Aubé reaction.
An efficient and convenient method for the synthesis of sugar-lactam conjugates is reported starting from readily available sugar azides using the Aubé reaction. Cyclic azido alcohols are used in the...
Chiral separation method development was carried out for eslicarbazepine acetate and its (R)-enantiomer on diverse chiral stationary phases. Better chiral selectivity was observed on cellulose tris-(3...
Synthesis of Molluscicidal Agent Cyanolide A Macrolactone from d-(-)-Pantolactone.
An efficient synthesis of potent molluscicidal agent cyanolide A, a glycosidic 16-membered macrolide, starting from d-(-)-pantolactone is reported. Highly stereoselective aldol, oxa-Michael addition,...
Total synthesis of isofregenedadiol (#).
The first total synthesis of isofregenedadiol, a bicyclic diterpene isolated from H. Viscosum, is reported starting from a d-(-)-pantolactone chiral pool. A one-pot quadruple reaction sequence compris...
A series of novel heterocyclic carboxylic acid based protein tyrosine phosphatase 1B (PTP1B) inhibitors with hydrophobic tail have been synthesized and characterized. Structure-activity relationship (...
Clinical Trials
None
Companies
Advinus Therapeutics is a research-based Pharmaceutical Company founded by leading global pharmaceutical executives and promoted by the TATA Group. The company is the first of its...
Aagami is a Contract Research Organization (CRO) providing its Drug Discovery and Development Services to Pharmaceutical and Biotech industries in early exploratory and full development phases. These...
More Information about "Advinus Therapeutics" on BioPortfolio
We have published hundreds of Advinus Therapeutics news stories on BioPortfolio along with dozens of Advinus Therapeutics Clinical Trials and PubMed Articles about Advinus Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Advinus Therapeutics Companies in our database. You can also find out about relevant Advinus Therapeutics Drugs and Medications on this site too.
